

## Special Issue

# Alzheimer's Disease: An Update on Novel Therapeutics

### Message from the Guest Editors

Although some reversible treatments for Alzheimer's disease (AD) have been suggested recently, this debilitating condition is still incurable. The majority of clinically recommended treatments today only attenuate the symptoms, enhancing AD patients' quality of life. Despite their ability to attenuate symptoms, these medicines lead to several side effects. The absence of treatments for AD is due to a number of factors, including not knowing the real mechanism of the disease, even though several mechanisms have been proposed in the literature; the drugs being limited in reaching the brain due to the existence of the blood-brain barrier; and others. Thus far, there is an urgent need to understand the disease mechanisms better and to develop novel treatments for AD. This Special Issue aims to collect the most recent advances in new treatments proposed for disease therapy.

### Guest Editors

Dr. Maria Carmo Pereira

Dr. Joana A. Loureiro

Dr. Maria João Ramalho

Dr. Stephanie Andrade

### Deadline for manuscript submissions

closed (20 June 2023)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/158524](https://mdpi.com/si/158524)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).